FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

BUSINESS AND MEDICINE Volume 352:531-533 February 10, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Consider the case of Sharon Saarinen. In 2002, the 38-year-old hairdresser traveled to Beirut in desperate pursuit of a baby. Four years earlier, she and her husband had had their first high-tech child, a daughter conceived through cytoplasmic transfer. In this process, fertility specialists remove a single egg from the mother-to-be and inject it with cytoplasm from the egg of another (usually younger) woman. The rejuvenated egg is inseminated with the father's sperm and inserted into the mother's uterus. The daughter that resulted in the Saarinens' case was apparently perfectly normal. Yet like any child conceived through cytoplasmic transfer, she . . . [Full Text of this Article]

Source Information

Dr. Spar is a professor of business administration at Harvard Business School, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.